Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5882914 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 11 Pages |
Abstract
Patients with CML-CP and mild to moderate renal or liver dysfunction can be safely treated with front-line dasatinib or nilotinib and can achieve response rates similar to those of patients with CML-CP without organ dysfunction.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Koji Sasaki, Amit Lahoti, Elias Jabbour, Preetesh Jain, Sherry Pierce, Gautam Borthakur, Naval Daver, Tapan Kadia, Naveen Pemmaraju, Alessandra Ferrajoli, Susan O'Brien, Hagop Kantarjian, Jorge Cortes,